MMR-varicella zoster virus vaccine - Merck Sharp & Dohme

Drug Profile

MMR-varicella zoster virus vaccine - Merck Sharp & Dohme

Alternative Names: MMR/Varivax; ProQuad

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Measles vaccines; Rubella vaccines; Varicella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Measles; Mumps; Rubella; Varicella zoster virus infections

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 13 Apr 2015 The vaccine is registered in the EU for Measles, Mumps, Rubella and Varicella zoster virus infections
  • 16 Mar 2012 The European Commission requests a review of the benefit-risk balance of ProQuad® in pregnant women and subjects with immune deficiencies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top